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Abstract 
Background: The gene variant Pro/Ala (rs1801282) in the PPARγ2 has been associated with 
lower cardiovascular risk and greater benefit from lifestyle interventions. This polymorphism 
also seems to be associated with longer lifespan, but no information on telomere length (TL) is 
available. Our aim was to study the association between the Ala allele and changes in TL in 
high cardiovascular risk subjects, and the potential interaction with a Mediterranean Diet 
(MeDiet) pattern. 
Methods and Results: A total of 521 subjects (55-80 years) participating in the Prevención con 
Dieta Mediterránea (PREDIMED) randomized trial were genotyped. Changes in TL, measured 
by quantitative real-time PCR, were assessed over 5 years of a nutritional intervention which 
promoted adherence to the MeDiet. Interestingly, Ala carriers showed lower telomere 
shortening after 5 years, compared with the Pro/Pro genotype (P=0.031). This association was 
modulated by MeDiet since those Ala carriers who reported better conformity to the MeDiet 
exhibited increased TL (P<0.001). Moreover, a reduction in carbohydrate intake (≤9.5 g/d) 
resulted in increased TL among Ala carriers. Notably, an apparent gene-diet interaction was 
found through the observed changes in the MUFA+PUFA/Carbohydrates ratio: as this ratio 
increased, TL lengthening was detected to a greater extent in the Ala carriers compared with the 
Pro/Pro subjects (P for interaction <0.001). 
Conclusions: The Pro12Ala polymorphism is associated with TL homeostasis after 5 years 
follow-up in subjects at high cardiovascular risk. In addition, a higher adherence to the MeDiet 
pattern strengthens the prevention of telomere shortening among Ala carriers.  
Clinical trial registration: URL: www.controlled-trials.com. Unique Identifier: 
ISRCTN35739639. 
Keywords: telomeres, nutrigenetics, nutrition, gene-diet interaction.  
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Telomeres are tandem TTAGGG repeats of DNA that, together with associated proteins, protect 
the ends of chromosomes.
1
  Importantly, they become shorter during repeated DNA replication 
and leukocyte telomere length (TL) has therefore been proposed as a potential biomarker of 
biological age.
2
 There are a number of endogenous factors that cause telomere shortening, such 
as inflammation or oxidative stress,
3-5
 and many age-related diseases, such as obesity
6, and 
cardiovascular disease
7
 are linked to shortened telomeres.
8,9
. Several studies indicate that 
patients with early-onset coronary heart disease; hypertension; and diabetes mellitus 
complications have lower TL, whilst increased left ventricular hypertrophy or ventricular mass 
is associated with higher TL.
10
 Moreover, telomere attrition is reported to be accelerated in 
endothelial cells in the regions affected by atherosclerosis
11, 12
 and in coronary endothelial cells 
it may contribute to coronary endothelial dysfunction and the progression of cardiovascular 
disease in humans.
13
 In this context, cardiovascular risk factors can be causes of oxidative stress 
and endothelial injury, leading to telomere shortening. 
There is evidence that TL is modified by the environment (poor diet, smoking, psychosocial 
factors)
6
 and also by non-environmental influences such as genetic
14
 or epigenetic factors
15
. In 
healthy individuals, the estimated heritability of TL ranges from 0.36 to 0.84.
16
 The impact of 
telomere pathway gene variants on TL has been widely studied, especially for single nucleotide 
polymorphisms (SNPs) encoding telomerase subunits.
17,18
 However, other GWAS studies have 
identified SNPs associated with TL which do not contain candidate genes of telomere biology, 
but rather genes related to several cancers and other diseases.
19, 20
 Recently, Saxena et al.
21
 
showed that variants in casein kinase II (CSNK2A2) are associated with leukocyte TL in a 
Punjabi Sikh Diabetic Cohort. 
The presence of the Ala allele in the peroxisome proliferator-activated receptor gamma 2 
(PPARγ2) results in a moderate reduction in transcriptional activity of the PPARγ2 in adipose 
tissue, thus improving insulin sensitivity and lipid and glucose homeostasis.
22, 23
 This gene 
variant seems to regulate inflammation by controlling downstream inflammatory molecules,
24
 
and it may decrease resistance to oxidative stress.
25
 Moreover, several studies have reported that 
4 
 
carriers of the Ala allele are considerably better protected against cardiovascular disease
26, 27
, 
and the effectiveness of primary prevention of cardiovascular disease by a lifestyle intervention 
even increased among them.
28, 29
  
Interestingly, it has been suggested that the presence of the Ala allele could be associated with 
longer lifespan in humans.
30, 31
 However, no further studies have examined the association of the 
Pro12Ala polymorphism and TL in high cardiovascular risk subjects after a Mediterranean diet 
(MeDiet) intervention. We hypothesized that subjects carrying the Ala allele of the PPARγ2 
gene would have lower telomere attrition after 5 years of intervention with a Mediterranean 
dietary pattern. Thus, our aim was to assess the relationship between the Ala allele of the 
PPARγ2 gene and changes in TL in high cardiovascular risk subjects, whilst they received a 
nutritional intervention with a Mediterranean dietary pattern.  
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Methods 
Study design 
The PREDIMED study was a large, parallel-group, multicenter, randomized and controlled 
clinical trial, designed to assess the effects of the MeDiet on the primary prevention of 
cardiovascular disease. All subjects provided informed consent and the protocol was approved 
by the Institutional Review Boards at all study locations, according to the principles of the 
Helsinki Declaration. The trial is registered at http://www.controlled-trials.com/ISRCTN 
35739639. Participants were randomly assigned one of three different dietary interventions: 
MeDiet supplemented with extra virgin olive oil (EVOO), MeDiet supplemented with mixed 
nuts, or a control group (low-fat diet). The design and methods of this trial have been reported 
in specific publications
32, 33
 and further details are also available at www.predimed.es. 
Participants were women (60 to 80 years old) or men (55 to 80 years old) without a history of 
cardiovascular disease, but at high cardiovascular risk. Inclusion criteria were either type-2 
diabetes mellitus or at least three of the following major cardiovascular risk factors: current 
smoking, hypertension, elevated low-density lipoprotein cholesterol, low high-density 
lipoprotein cholesterol, overweight/obese, and family history of premature coronary heart 
disease. 
This study was designed to assess TL in a subset of participants from one of the eleven 
recruitment centers (PREDIMED-NAVARRA). The PREDIMED-NAVARRA recruitment 
center was the first of the eleven centers to complete the enrolment of participants, comprising 
1055 of the 7447 subjects taking part in the trial. Individuals from this center were recruited 
between June 2003-May 2005, whilst in the rest of the centers it took place between October 
2003 and March 2009. The intervention was stopped in 2011 due to early evidence of benefit, 
according to a joint decision of the Data and Safety Monitoring Board and the Steering 
Committee of the study. 
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From the PREDIMED-NAVARRA total sample, participants with either baseline or 5-year 
missing data or missing DNA samples were excluded from the TL analysis. Therefore, 521 
subjects were included in this study. They did not differ from the total cohort (n=1,055) in terms 
of their main characteristics. Among them, 211 participants were allocated to the MeDiet 
supplemented with EVOO group, 170 to the MeDiet supplemented with mixed nuts group and 
140 to the Control group (Fig. 1).  
Genotyping 
DNA was extracted from overnight fasting venous blood samples using a commercial kit 
(Master PureTM; Epicentre, Madison, WI, USA). All participants were genotyped for the 
Pro12Ala polymorphism of the PPARγ2 gene (rs1801282) using the PCR-restriction fragment 
length polymorphism (RFLP) method as previously described.
34
 
Telomere length assessment 
Telomeres were measured at two points: at baseline and after 5 years of the nutritional 
intervention using a real-time quantitative polymerase chain reaction (qPCR), as described by 
Cawthon.
35
 This method displays concentrations of telomere repeat copy number (T) and single-
copy gene (Ribosomal Protein Large PO) copy number (S), as a reference for each sample. 
White 384-well plates were used to perform PCRs on an ABI-Applied Biosystems 7900 HT 
thermal cycler (Applied Biosystems, CA, USA). The total reaction volume was 10 μL 
containing 10 ng of genomic DNA, and quantiTect Syber Green PCR kit (Qiagen, Valencia, 
CA, USA) was used as master mix. The final telomere primer concentrations were as follows: 
for telomere amplification tel1, 675 nmol/L and for tel2, 1350 nmol/L; and for the amplification 
of the single copy gene RPLPO: hRPLPO1, 800 nmol/L; hRPLPO2, 800 nmol/L. The primer 
sequences (Sigma-Aldrich, St.Louis, MO, USA) were tel1 (5’-
GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3’), tel2 (5’-
TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3’), hRPLPO1 (5’-
CCCATTCTATCATCAACGGGTACAA -3’) and hRPLPO2 (5’-
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CAGCAAGTGGGAAGGTGTAATCC -3’). This procedure normalizes T to S by taking the 
ratio (T/S ratio) for each sample. The T/S ratio was calculated as follows [2
CT(telomeres)/
2
CT(single copy 
gene)
]
 
= 2
-∆CT
, since the amount of the PCR product approximately doubles in each cycle of the 
PCR.
35
 
A calibration curve of the same DNA reference sample (64-0.25 ng in 2-fold dilutions) was 
included for each measurement as a standard, to control the day-to-day variations. Standard 
curve with linearity R
2
> 0.98 was accepted. For quality control, all samples were run in 
duplicate, and concordance between duplicate values was checked. In order to ensure 
consistency, samples showing a high variation (more than 10%) were rerun and reanalyzed. The 
intra-assay coefficient of variation between duplicates for telomere was 3.0% and for the single 
copy gene it was 2.6%. The inter-assay coefficient of variation between plates for telomere was 
0.8% and for the single copy gene it was 1.3%. The small coefficients of variation support the 
reliability of this procedure. 
 Dietary assessment 
Dietary habits were evaluated using a semi-quantitative 137-item Food frequency Questionnaire 
previously validated in Spain.
36
 Frequency of consumption was registered in nine categories that 
ranged from ‘never or almost never’ to ‘6 times/day’. In addition, a validated 14-item 
questionnaire was used in this study to appraise adherence of participants to the MeDiet.
37
  
The two groups which were allocated MeDiets received intensive education to be able to follow 
the MeDiet, and supplemental foods at no cost. EVOO (1 L/week) was provided to the first 
group and 30 g/day of mixed nuts (15 g walnuts, 7.5 g hazelnuts and 7.5 g almonds) to the 
second group. In the control group, participants did not receive education on the MeDiet, but 
were advised to reduce all types of fat and were given written recommendations according to 
the American Heart Association guidelines. Each participant received a personal interview with 
a trained dietician and a group session conducted by the same dietician every 3 months during 
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the 5 years. No energy restrictions were prescribed for any intervention group. Other specific 
details of the intervention protocol have been published elsewhere.
33
 
Confounders assessment 
The baseline interview included information about medical, socio-demographic and lifestyle 
variables. Physical activity was assessed through a validated physical activity questionnaire.
38, 39
 
Anthropometric data were obtained by trained dieticians using standardized methods
40
 and were 
measured in each of the yearly follow-up visits. Educational attainment was used as the 
indicator of socioeconomic status, since it does not change much over a lifetime, and – either 
directly or indirectly – it affects an individual’s adoption of health behaviors and their 
outcomes. 
Statistical analysis 
Hardy-Weinberg equilibrium was assessed using the χ2 test and the allele frequency was 
determined by direct counting. Participants’ baseline characteristics were compared according 
to the Pro12Ala PPARγ2 polymorphism (dominant models). All analyses were carried out with 
the dominant genetic model due to the small sample of Ala/Ala homozygotes. At baseline, we 
calculated means and standard deviations (SD) or percentages for each variable across the two 
genotypes and assessed the statistical significance of the differences among them with the 
unpaired t-test and χ2 tests, respectively. 
To determine modulation by dietary components, changes in macronutrients after the 5-year 
nutritional intervention were dichotomized based on individual’s median levels, with the 
exception of the 14-item questionnaire that was divided into tertiles. The ratio 
(MUFA+PUFA)/CHO was also evaluated as a continuous variable. Indicated interactions 
between the gene variant (dichotomous) and all the dietary components were tested for TL 
changes using the likelihood ratio tests. When the dietary component was a dichotomous 
variable the interaction test had 1 degree of freedom, whereas the interaction test had 2 degrees 
of freedom in the case of a dietary component that was categorized into three groups, without 
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assuming any linear effect. Changes in TL and dietary habits were deﬁned as the difference 
between the two points in time (baseline and 5-year follow-up). 
The comparison between-genotype differences in TL within each dietary category was assessed 
using ANCOVA techniques after adjusting for the following potential confounders measured at 
baseline: age, sex, body mass index (BMI) (kg/m
2
), TL, smoking habit (current smoker or never 
smoker), physical activity (METS-min/day), total energy intake (Kcal/day) and the score 
obtained from the 14-item MeDiet tool. In additional analyses, the model was also adjusted for 
each initial dietary component as indicated in the Results section.  
We achieved a statistical power higher than 80% (alpha-level=0.05 and beta-level=0.20), with a 
sample size of 521 and a prevalence of 13% in Ala allele carriers, when detecting significant 
mean differences of 40 arbitrary units in TL between both genetic variants, after adjusting for 
potential confounders. All P values presented are two-tailed and statistical signiﬁcance was 
deﬁned at P<0.05. Data analyses were performed using STATA version 12.0 (StataCorp, 
College Station, TX, USA).  
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Results 
The mean age of participants was: 67.0 years (DE: ±6.0), and 54.7% of them were women. The 
overall frequencies of the Pro/Pro, Pro/Ala and Ala/Ala genotypes were 86.7%, 13.1% and 
0.2%, respectively. The minor allele frequency of Ala allele was 0.067, which is similar to 
0.076 in HapMap-CEU (European) subjects as recorded in the NCBI SNP database.
41
 The 
genotype frequency did not deviate from the Hardy-Weinberg equilibrium expectations 
(P=0.344). All analyses were undertaken with a dominant genetic model due to the small 
number of Ala/Ala homozygotes.  
Baseline characteristics of the 521 participants according to the Pro12Ala polymorphism are 
presented in Table 1. Most of them were overweight or obese (92%), non-smokers, and more 
than three-quarters had hypertension. No significant differences were observed for the Pro12Ala 
polymorphism in this population. Specifically, no differences were observed for adherence to 
MeDiet with the 14-item questionnaire, within the Pro12Ala gene variant (p=0.616), meaning 
that they have a similar adherence to Mediterranean diet at enrolment. However it should be 
highlighted that carriers of the Ala allele tended to have higher TL (p=0.095).  
As expected, TL was negatively associated with age in this population both at baseline (rho=-
0.104, p=0.018) and after the 5-years nutritional intervention (rho=-0.124, p=0.004) (data not 
shown). Remarkably, the 5-year MeDiet intervention did prevent telomere shortening and even 
increased TL among Ala carriers, whilst this effect was not observed in Pro/Pro homozygotes 
after adjusting for potential confounders (PANCOVA= 0.031) (Fig. 2).  
We assessed the effects of changes in the dietary pattern, as categorical factors, after the 
intervention on telomere lengthening linked to the PPARγ2 Pro/Ala gene variant, using 
multivariable-adjusted analysis (Table 2). Interestingly, an increased TL was detected when 
subjects reported better conformity to the MeDiet (14-item score) after the intervention, but only 
in subjects carrying the Ala allele of the PPARγ2 gene (PANCOVA<0.001). The interaction for 
modifications in TL between changes in adherence to MeDiet and the PPARγ2 gene was also 
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statistically significant (P for interaction= 0.016). Moreover, the presence of the Ala allele 
increased TL in subjects with a greater reduction in carbohydrates (CHO) intake (≤9.5 g/d) after 
5 years in comparison with Pro/Pro participants (PANCOVA= 0.006). Notably, there was evidence 
of statistical interaction (P for interaction= 0.007). Similar results were observed when 
individuals with the Pro/Ala genotype reduced glycemic load intake (≤ 5) (PANCOVA= 0.004; P 
for interaction= 0.004).  
As the nutritional intervention promoted increased intake of unsaturated fats (MUFA+PUFA) at 
the expense of reduced CHO intake, we assessed whether changes in the ratio unsaturated 
fat:CHO modulated the relationship between Pro12Ala polymorphism and changes in TL.We 
found a modulation of the genetic predisposition to TL changes by the unsaturated fat:CHO 
ratio (Fig. 3). The prediction plot showed a gene-nutrient interaction: as the unsaturated 
fat:CHO ratio increased, TL was predicted to increase only in the Ala carriers and not in the 
Pro/Pro homozygotes (P for interaction <0.001). 
When considering the items included in the 14-item MeDiet score separately, we found that 
higher consumptions of virgin olive oil, vegetables, fruits and the use of sofrito sauce during 
follow-up, were significantly associated with increased TL, but again, this association was only 
present in the Ala carriers; whereas a lower consumption of red meat, butter/margarine/cream, 
soda drinks, commercial sweets and confectionery led to decreased telomere attrition, also only 
among these subjects (Supplemental table 1). Contrary to expectations, subjects carrying the 
Ala allele consuming less wine, legumes, fish/seafood and tree nuts exhibited an increase in TL 
after adjusting for potential confounders. 
Analysis performed on an intention-to-treat basis showed no differences in TL changes after 5 
years in any of the intervention groups (EVOO, Nuts and Control) after splitting the sample 
according to the Pro/Pro and Pro/Ala genotypes (Table 3). However, when distributing subjects 
according to the intervention group and changes in adherence to MeDiet, only Ala carriers with 
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higher scores in the MeDiet screener and allocated to one intervention group, either EVOO or 
Nuts, prevented telomere shortening (Fig. 4).  
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Discussion 
To our knowledge this is the first study to report an association between the common genetic 
variant at the PPARγ2 locus, rs1801282, and TL, in which the Ala allele prevented telomere 
shortening associated with age after a 5-year nutritional intervention in high cardiovascular risk 
subjects. In addition, it has been shown that a Mediterranean dietary pattern interacts with the 
Ala allele, resulting in higher TL. 
This Ala variant has been associated with lower cardiovascular disease risk in some studies.
27, 28
 
Regieli et al.
27
 showed that Ala allele carriers had less widespread coronary artery disease and 
were protected against 10-year cardiovascular morbidity and mortality, with a hazard ratio of 
0.24 (0.08-0.74, P= 0.013) for vascular death, per each added copy of Ala allele. It is also 
reported that lifestyle interventions for cardiovascular prevention are more effective in carriers 
of the Ala allele of the PPARγ2 gene than in those with the Pro/Pro genotype.28, 29 Since shorter 
telomeres have been found in subjects with cardiovascular disease,
7
 it could be suggested that 
the Pro/Ala genotype may potentially protect against telomere attrition, as observed in our 
population at high cardiovascular risk. 
Of particular interest is the reported relationship between the presence of the Ala allele and 
longevity, as TL is considered a biomarker for age.
2
 Work conducted by Luo et al.
25
 showed 
that PPARγ2 heterozygous mice exhibited improvement in insulin sensitivity and increased 
resistance to oxidative stress, underlying an extended lifespan. Another study indicated that 
Pro/Ala mice seem to be leaner, with improved insulin sensitivity and plasma lipid profiles, and 
have longer lifespans.
42
 Notably, this evidence has been supported in a human study performed 
on a group of centenarian men who had increased frequency of the Pro/Ala genotype.
30
 In 
contrast, however, a recent study proposed the opposite, having found a high frequency of the 
Ala allele in men younger than 90 years old.
31
 Our findings give valuable information in 
longitudinal terms, by suggesting PPARγ2 as a possible longevity candidate gene, since the Ala 
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allele was associated with telomere lengthening in multiple-adjusted models after 5 years of a 
nutritional intervention.  
The response of subjects to dietary components might be different depending on the genotype. 
In the population studied, we found a consistent gene-diet interaction between the Pro/Ala gene 
variant and adherence to MeDiet for changes in TL after the intervention. There are few 
examples in the literature on the subject of the influence of a MeDiet on maintaining TL. There 
are two potential mechanisms that account for changes in TL: one may occur through 
telomerase-mediated elongation, and the other by mechanisms resulting in "pseudo-telomeric 
lengthening", as might result from changes in cell type distribution.
43
 Boccardi et al. 
44
 showed 
that people with the highest adherence to a MeDiet have longer telomeres and higher telomerase 
activity levels in peripheral white blood cells, independently of multiple confounding variables. 
This positive effect of the MedDiet could be direct, through some specific nutrients that may 
stimulate telomerase activity, or indirect, through the global effect of the diet on the modulation 
of inflammation and oxidative status.
44
 
With regard to this, oxidative stress and inflammation might be proposed as the underlying 
causes of accelerated telomere shortening.
5
 Interestingly, the Ala allele has been associated with 
lower levels of inflammation and oxidative stress
24, 25
 On the other hand, activation of PPARγ2 
can inhibit telomerase activity,
45
 elucidating a potential relationship between this gene and TL. 
Since, the Pro12Ala variant is associated with lower PPARγ2 activity,23 it may be hypothesized 
that this effect of the Ala allele is mediated by telomerase activity. Nevertheless, we could not 
rule out inflammation and oxidative stress as other mechanisms implicated in the change. Our 
findings need to be further explored in other populations to better understand this biological 
mechanism.  
Surprisingly, no significant interaction was observed between the intervention groups 
established in the PREDIMED study (on an intention-to-treat basis) and the polymorphism for 
changes in TL. Nevertheless, when analyzing the adherence to the MeDiet within each group, 
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we observed a significantly more increased TL in Ala carriers than in Pro/Pro homozygotes 
when the compliance to MeDiet was high, both in the EVOO and in the nuts group, but not in 
the control group. A possible explanation could be that these two groups presented a higher 
adherence to MeDiet as they received intensive education to follow MeDiet and supplemental 
foods at no cost. Thus, it should be highlighted that the MeDiet pattern itself had the positive, 
principal effect on the association between the Pro/Ala genotype and TL changes. 
Several limitations should be acknowledged. Firstly, that TL has several weaknesses given the 
extent of inter-individual variation at a given chronological age.
46, 47
 Moreover, there are some 
methodological problems due to TL measurement techniques. For this reason, we looked after 
the experimental conditions carefully, in order to avoid potential errors in measurement.
48
 
Genomic DNA was processed following a standardized protocol and kept to preserve its 
stability, and the two DNA samples per participant (at baseline and after 5 years of recruitment) 
were run on the same plate. Secondly, the lack of several biological measurements, such as 
telomerase activity and others related to inflammation and oxidative stress. Nor do we have 
information on the epigenetics profile status of participants.  
Another weakness of this study was the self-reported dietary consumption using questionnaires 
that might have led to misclassifications of exposure. Our participants lived in a MeDiet country 
and had high cardiovascular risk, which may also limit the generalizability of our findings. On 
the other hand, the prospective nature of our study, with a long follow-up period, enabled us to 
measure TL at two points in the context of a MeDiet intervention and thus makes this research 
particularly robust. Other strengths include: the randomized design, the high compliance of the 
participants to the intervention and the reproduction of real-time conditions with home-prepared 
foods, as in usual clinical practice. 
In summary, our results are in line with previous finding on the great beneficial effect of a 
lifestyle intervention on Ala carriers who are high cardiovascular risk subjects.  Specifically, we 
demonstrated an increased TL in Ala carriers after 5 years of a MeDiet intervention, suggesting 
16 
 
that the MeDiet pattern appears to have a beneficial effect in modulating the association 
between the polymorphism and changes in TL. Understanding the underlying mechanism of this 
gene-diet interaction may help to improve personalized dietary recommendations to prevent 
cardiovascular risk factors. However, to date, this is apparently the only study to report these 
results, and therefore further investigation is warranted to confirm our findings.  
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Table 1. Baseline characteristics according to the PPARγ2 genotype among all the participants. 
* Values are means and standard deviations (SD) for continuous variables or percentages for categorical 
variables. 
† BMI, body mass index; MeDiet, Mediterranean Diet.  
 Pro/Pro Ala carriers  P value 
n 451 70  
Male/female, % 46/54 36/64 0.106 
Age, y 66.9 (5.9) 68.1 (5.7) 0.101 
Socioeconomic status   0.395 
Low level, % 75.8 71.1  
High level, % 24.2 29.0  
BMI, kg/m
2 
29.2 (3.2) 28.9 (3.2) 0.482 
Waist, cm 95.3 (10.1) 94.0 (7.9) 0.313 
Physical activity, METs-min per day 276.2 (197.3) 283.9 (189.2) 0.763 
Adherence to the MeDiet, points 9.1 (1.9) 9.3 (1.7) 0.616 
Dietary intake    
Energy intake, Kcal/day 2258.2 (526.8) 2210.5 (530.5) 0.485 
Carbohydrates,  % energy 40.0  41.2  0.150 
Fat, % energy 40.6  40.0  0.460 
Protein, % energy 15.9  16.1  0.560 
Glycemic  load 125.0 (43.3) 124.8 (49.2) 0.977 
Intervention groups   0.732 
MeDiet+olive oil, % 39.9 44.9  
MeDiet+nuts, % 32.8 30.4  
Control, % 27.3 24.6  
Current smokers, % 15.3 11.6 0.407 
Diabetes, % 36.1 39.1 0.633 
Hypertension, % 83.6 81.2 0.619 
Dyslipidemia, % 65.0 73.9 0.136 
Telomere length, T/S ratio 258.3 (453.8) 368.3 (781.9) 0.095 
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Table 2. Interactions between PPARγ2 and changes in adherence to MeDiet, CHO intake, 
glycemic load and ratio (MUFA+PUFA)/ CHO in association with changes in telomere length 
after 5 years of the nutritional intervention. 
*Adjusted for age, sex, basal BMI, basal telomere length, physical activity (METS-min per day), total 
energy intake (Kcal per day), total 14-point score at baseline and smoking status (dichotomous).  
† MeDiet, Mediterranean Diet; CHO, carbohydrates; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids. 
‡
 Additionally adjusted for basal CHO intake. 
§
 Additionally adjusted for basal Glycemic load. 
| |
 Additionally adjusted for basal ratio (MUFA+PUFA)/CHO. 
#
 P-values are for the comparison between-genotype differences in telomere length within each dietary 
category after our corresponding adjustment for potential confounders.  
 Δ Telomere length   
 Pro/Pro Ala carriers P 
value
#
 
P for 
interaction 
Δ Adherence MeDiet, score points    0.016 
Low < 1 (n=240) -57.2 (-88.0 to -26.3) -98.1 (-176.3 to -20.0) 0.342  
Medium 2-3 (n=180) -40.8 (-109.6 to 27.8) 141.0 (-40.9 to 323.0) 0.070  
High > 4 (n=101) -121.9 (-176.5 to -67.3) 160.4 (9.5 to 311.3) <0.001  
Δ CHO intake, g/d ‡    0.007 
Below median: ≤ 9.5 (n=260) -76.6 (-128.7 to -24.6) 131.2 (-6.8 to 269.1) 0.006  
Above median: > 9.5 (n=261) -47.0 (-74.7 to -19.3) -86.8 (-157.3 to -16.3) 0.307  
Δ Glycemic load, units  §    0.004 
Below median: ≤ 5.0 (n=260) -80.4 (-132.0 to -28.9) 144.4 (-0.7 to 289.4) 0.004  
Above median: > 5.0 (n=261) -44.8 (-73.3 to -16.3) -68.1 (-136.9 to 0.6) 0.541  
Δ (MUFA+PUFA)/ Δ CHO | |    0.092 
Below median: ≤ 0.03 (n=260) -39.1 (-69.4 to -8.8) -33.7 (-106.7 to 39.3) 0.894  
Above median: > 0.03 (n=261) -84.8 (-134.8 to -34.8) 92.0 (-48.9 to 232.9) 0.022  
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Table 3. Changes in telomere length after 5 years of the nutritional intervention associated with 
Pro12Ala polymorphism according to groups of intervention. 
* Adjusted for age, sex, basal BMI, basal telomere length, physical activity (METS-min per day), total 
energy intake (Kcal per day), total 14-point score at baseline and smoking status (dichotomous). 
†
 P-values are for the comparison between-genotype differences in telomere length within each dietary 
category after our corresponding adjustment for potential confounders   
 Δ Telomere length   
 Pro/Pro Ala carriers P value† P for 
interaction 
Group of intervention
    0.737 
   Control 7.5 (-17.7 to 32.8) 39.1 (-31.0 to 109.1) 0.412  
   Extra virgin olive oil -137.5 (-199.7 to -75.2) -52.6 (-204.7 to 99.4) 0.315  
   Nuts -26.2 (-68.9 to 16.6) 93.2 (-22.5 to 208.9) 0.061  
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Figures legends 
Figure 1. Flowchart of participants in a subsample of the PREDIMED-NAVARRA trial. 
MeDiet: Mediterranean Diet. 
Figure 2. Effect of the rs1801282 polymorphism of the PPARγ2 gene on changes in telomere 
length after 5 years of a nutritional intervention in the frame of the PREDIMED-NAVARRA 
trial (n=521). Multivariate adjusted means for telomere length changes depending on the 
polymorphism, adjusted for age, sex, baseline telomere length, BMI (kg/m
2
),  physical activity 
(METS-min per day), total energy intake (Kcal per day), total 14-point score at baseline and 
smoking status (dichotomous). 
Figure 3. Interaction between the rs1801282 polymorphism of the PPARγ2 gene with changes 
in the ratio (MUFA+PUFA)/Carbohydrates in determining changes in telomere length after 5 
years of the nutritional intervention in the frame of the PREDIMED-NAVARRA trial (n=521). 
P for interaction was adjusted for age, sex, baseline telomere length, baseline ratio 
MUFA+PUFA/carbohydrates, BMI (kg/m
2
), physical activity (METS-min per day), total energy 
intake (Kcal per day), total 14-point score at baseline and smoking status (dichotomous). The 
two following equations correspond to both regression lines, Pro/Pro genotype (blue line): y= 
2.83 + 6.52 x; Ala carriers (red line):  y= -106.76 + 1398 x. 
Figure 4. Changes in telomere length after 5 years of the nutritional intervention associated 
with Pro12Ala polymorphism, according to the group of intervention and tertiles of adherence 
to the Mediterranean Diet (14-item questionnaire) at follow-up. Means and SD for telomere 
length are adjusted for age, sex, basal telomere length, BMI (kg/m
2
), physical activity (METS-
min per day), total energy intake (Kcal per day), total 14-point score at baseline and smoking 
status (dichotomous). * P< 0.025, 
#
 P=0.070 are P values comparing Ala carriers vs. Pro/Pro 
subjects within the three groups of intervention. 
 




SUPPLEMENTAL MATERIAL 
Supplemental table 1. Changes in telomere length after the nutritional intervention associated with the Pro12Ala polymorphism according to the fulfilment of 
each item included in the 14-point screener of adherence to the Mediterranean diet at year 5. 
  Δ Telomere length   
Adherence to MeDiet at follow-up % Pro/Pro Ala carriers P value P for interaction 
1. Use of olive oil as main culinary lipid Yes (98.8) -65.3 (-95.2 to -35.5) 28.6 (-48.9 to 106.2) 0.027 0.209 
 No (1.2) - - -  
2. Olive oil >4 tablespoons Yes (84.8) -78.3 (-112.7 to -44.0) 28.9 (-59.0 to 116.8) 0.027 0.243 
 No  (15.2) 19.6 (-18.2 to 57.4) -26.3 (-132.9 to 80.2) 0.430  
3. Vegetables ≥2 servings/d Yes (72.3) -82.6 (-121.0 to -44.1) 47.2 (-50.7 to 145.1) 0.016 0.124 
 No (27.7) -15.2 (-53.0 to 22.5) -42.6 (-147.3 to 62.0) 0.632  
4. Fruits ≥3 servings/d Yes (74.8) -55.0 (-92.7 to -17.4) 57.9 (-40.5 to 156.3) 0.037 0.376 
 No (25.2) -89.7 (-125.3 to -54.1) -64.6 (-155.9 to 26.5) 0.619  
5. Red/processed meats <1/d Yes (98.8) -62.7 (-92.7 to -32.6) 24.3 (-52.9 to 101.5) 0.041 - 
 No (1.2) - - -  
6. Butter, cream, margarine <1/d Yes (97.5) -61.2 (-91.5 to -30.8) 30.0 (-48.2 to 108.2) 0.034 0.538 
 No (2.5) -151.8 (-207.8 to -95.8) -336.4 (-563.3 to -109.4) 0.227  
7. Soda drinks <1/d Yes (98.3) -61.1 (-91.2 to -31.0) 25.1 (-52.1 to 102.3) 0.042 - 
 No (1.7) - - -  
8. Wine glasses ≥7/wk Yes (36.9) -62.9 (-108.1 to -17.7) -39.4 (-162.9 to 84.0) 0.729 0.443 
 No (63.1) -62.9 (-102.1 to -23.8) 52.7 (-47.0 to 152.4) 0.035  
9. Legumes ≥3/wk Yes (25.6) -29.9 (-71.7 to 11.9) -146.9 (-257.7 to -36.2) 0.056 0.007 
 No (74.4) -74.9 (-111.8 to -38.0) 80.4 (-15.1 to 175.9) 0.003  
* Adjusted for age, sex, basal BMI, basal telomere length, physical activity (METS-min per day), total energy intake (Kcal per day), smoking status (dichotomous) 
and the total 14-point score at baseline. 
† MeDiet, Mediterranean Diet 
10. Fish/seafood ≥3/wk Yes (70.2) -78.7 (-110.8 to -46.6) -53.9 (-138.9 to 31.2) 0.593 0.014 
 No (29.8) -32.0 (-94.6 to 30.7) 216.1 (55.2 to 377.0) 0.006  
11. Commercial sweets and confectionary ≤2/wk Yes (88.8) -66.9 (-99.1 to -34.7) 28.4 (-55.3 to 112.1) 0.038 0.681 
 No (11.2) -37.2 (-103.0 to 28.7) -1.5 (-169.8 to 166.9) 0.702  
12. Tree nuts ≥3/wk Yes (61.0) -83.4 (-118.9 to -47.8) -25.3 (-123.6 to 72.9) 0.278 0.302 
 No (39.0) -33.9 (-83.0 to 15.2) 97.4 (-20.1 to 215.0) 0.046  
13. Poultry more than red meats Yes (86.5) -61.1 (-93.7 to -28.4) 24.9 (-63.3 to 113.1) 0.074 0.679 
 No (13.5) -84.3 (-150.0 to -18.7) 36.1 (-105.2 to 177.74) 0.142  
14. Use of sofrito sauce ≥2/wk Yes (88.8) -69.4 (-102.6 to -36.3) 33.0 (-52.4 to 118.4) 0.029 0.329 
 No (11.2) -9.2 (-41.0 to 22.6) -111.2 (-211.1 to -11.3) 0.072  
